Skip to main content
NBIX
NASDAQ Life Sciences

Neurocrine Reports Strong Q1 Earnings, Announces $2.9 Billion Acquisition of Soleno Therapeutics, and Reaffirms 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$139.08
Mkt Cap
$13.555B
52W Low
$108.35
52W High
$160.18
52W Position info
28% above low
Off High info
13% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

NBIX sits 28% above its 52-week low of $108.35.

Summary

Neurocrine Biosciences reported significantly strong first-quarter 2026 financial results, including a 44% increase in net product sales and a substantial rise in GAAP EPS, alongside announcing a definitive agreement to acquire Soleno Therapeutics for $2.9 billion.


Key Events · M&A and Partnerships · NBIX

  • Strong First-Quarter 2026 Financial Results

    Total net product sales increased 44% year-over-year to $811.0 million. GAAP diluted earnings per share rose significantly to $1.91 from $0.08 in the prior-year period, driven by strong demand for INGREZZA and CRENESSITY.

  • Definitive Agreement to Acquire Soleno Therapeutics

    Neurocrine entered into an agreement to acquire Soleno Therapeutics for $2.9 billion in cash, adding VYKAT™ XR for Prader-Willi syndrome and expanding its endocrinology and rare disease portfolio. The acquisition is expected to close in Q2 2026.

  • Reaffirmed Full-Year 2026 Financial Guidance

    The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion, along with R&D and SG&A expense guidance, excluding post-close expenses from the Soleno acquisition.

  • Advancements in Clinical Pipeline

    Neurocrine initiated a Phase 2 clinical study for NBI-1117570 in adults with schizophrenia and a Phase 1 study for NBIP-'2118, a potential first-in-class therapy for obesity.


Analysis · NBIX · Life Sciences

Neurocrine Biosciences delivered exceptionally strong first-quarter results, with total net product sales increasing 44% year-over-year and GAAP diluted EPS surging from $0.08 to $1.91. This robust financial performance is further amplified by the definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move that significantly expands Neurocrine's portfolio with VYKAT™ XR for Prader-Willi syndrome and is expected to accelerate future revenue growth. The reaffirmation of full-year 2026 guidance, despite the strong Q1, suggests management's confidence in continued performance, while new clinical study initiations highlight ongoing pipeline development. This filing presents a highly positive outlook, combining strong operational execution with a major strategic acquisition.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NBIX was trading at $139.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $108.35 to $160.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBIX - Latest Insights

NBIX
Nov 03, 2026, 2:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $168.29
Real-time Price: $162.18 info
Change: -$6.11 (-4%) info
Market Cap: $16.401B info
NBIX
Nov 02, 2026, 4:50 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $157.48
Real-time Price: $162.18 info
Change: +$4.70 (+3%) info
Market Cap: $16.401B info
NBIX
Nov 02, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $146.96
Real-time Price: $162.18 info
Change: +$15.22 (+10%) info
Market Cap: $16.401B info
NBIX
Nov 02, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $145.35
Real-time Price: $162.18 info
Change: +$16.83 (+12%) info
Market Cap: $16.401B info
NBIX
Aug 26, 2026, 3:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.37
Real-time Price: $162.18 info
Change: +$8.81 (+6%) info
Market Cap: $16.401B info